| ATR | Ataxia telangiectasia and Rad3-related kinase |
| ATRi | ATR inhibitor |
| CamR | Camonsertib-resistant |
| CHK1 | Cell cycle checkpoint kinase 1 |
| CHK1i | Cell cycle checkpoint kinase 1 inhibitor |
| CNH | Copy-number-high |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| DEG | Differentially expressed gene |
| EC | Endometrial cancer |
| ECM | Extracellular matrix |
| EDN1 | Endothelin-1 |
| EMT | Epithelial–mesenchymal transition |
| FDR | False discovery rate |
| GDF15 | Growth/differentiation factor 15 |
| GO | Gene ontology |
| GSEA | Gene set enrichment analysis |
| IL6 | Interleukin 6 |
| JAK | Janus kinases |
| MSI-h | Microsatellite instability-high |
| NES | Normalized enrichment score |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| padj | Benjamini–Hochberg adjusted p-value |
| PrexR | Prexasertib-resistant |
| STAT3 | Signal transducer and activator of tanscription 3 |
| TENM2 | Teneurin-2 |
| THBS1 | Thrombospondin-1 |
| TNFα | Tumor necrosis factor-alpha |